Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25338764 | 1.00 | KRAS (0.47) | KRAS | |
| SCHEMBL31323467 | 0.91 | KRAS (0.38) | KRAS | |
| SCHEMBL25245870 | 0.90 | KRAS (0.39) | KRAS | |
| SCHEMBL25245868 | 0.90 | KRAS (0.39) | KRAS | |
| SCHEMBL25336659 | 0.89 | KRAS (0.45) | KRAS | |
| SCHEMBL30923047 | 0.89 | KRAS (0.49) | KRAS | |
| SCHEMBL25253561 | 0.87 | KRAS (0.43) | KRAS | |
| SCHEMBL30430356 | 0.87 | KRAS (0.43) | KRAS | |
| SCHEMBL25253562 | 0.87 | KRAS (0.43) | KRAS | |
| SCHEMBL25336240 | 0.87 | KRAS (0.45) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4436571-A1 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | Merck Sharp & Dohme LLC (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-118302162-A | Small molecule inhibitors of KRAS muteins | 默沙东有限责任公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20240025907-A1 | QUINAZOLINE PAN-KRas INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2023150284-A2 | QUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023097227-A1 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | MERCK SHARP & DOHME LLC (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097227-A1 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | MERCK SHARP & DOHME LLC (US) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025907-A1 | QUINAZOLINE PAN-KRas INHIBITORS | KRAS, NRAS, HRAS | KRAS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.